Profile data is unavailable for this security.
About the company
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. It is developing and commercializing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, mycosis fungoides (MF) and diffuse large B-cell lymphoma (DLBCL). The Company’s product candidate, eltanexor, oral SINE compound that, like selinexor, selectively blocks the nuclear export protein XPO1.
- Revenue in USD (TTM)146.03m
- Net income in USD-143.10m
- Incorporated2008
- Employees325.00
- LocationKaryopharm Therapeutics Inc85 Wells AveNEWTON CENTER 02459-3298United StatesUSA
- Phone+1 (617) 658-0600
- Fax+1 (302) 655-5049
- Websitehttps://karyopharm.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hongchang International Co Ltd | 2.68m | -378.79k | 115.49m | 8.00 | -- | 2.85 | -- | 43.16 | -0.0009 | -0.0009 | 0.0071 | 0.078 | 0.1065 | -- | 2.78 | -- | -1.51 | -7.98 | -1.60 | -10.94 | 2.59 | 11.47 | -14.16 | -64.88 | 3.74 | -- | 0.1417 | -- | 3,289.22 | -- | -42.63 | -- | -- | -- |
| Nuvectis Pharma Inc | 0.00 | -22.26m | 115.68m | 13.00 | -- | 9.29 | -- | -- | -1.42 | -1.42 | 0.00 | 0.7005 | 0.00 | -- | -- | 0.00 | -112.45 | -- | -168.51 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -16.64 | -- | -- | -- |
| Vor Biopharma Inc | 0.00 | -117.86m | 115.97m | 168.00 | -- | 0.7657 | -- | -- | -1.75 | -1.75 | 0.00 | 2.22 | 0.00 | -- | -- | 0.00 | -47.38 | -45.79 | -50.28 | -48.98 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.98 | -- | -- | -- |
| Citius Pharmaceuticals Inc | 0.00 | -39.33m | 116.55m | 22.00 | -- | 1.37 | -- | -- | -0.255 | -0.255 | 0.00 | 0.533 | 0.00 | -- | -- | 0.00 | -36.52 | -30.26 | -38.61 | -32.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -0.1589 | -- | -- | -- |
| PDS Biotechnology Corp | 0.00 | -42.94m | 119.57m | 25.00 | -- | 4.13 | -- | -- | -1.39 | -1.39 | 0.00 | 0.7896 | 0.00 | -- | -- | 0.00 | -62.97 | -51.63 | -76.04 | -59.00 | -- | -- | -- | -- | -- | -33.04 | 0.4772 | -- | -- | -- | -5.11 | -- | -- | -- |
| Amylyx Pharmaceuticals Inc | 380.79m | 49.27m | 120.65m | 384.00 | 2.53 | 0.2781 | 2.40 | 0.3169 | 0.7045 | 0.7045 | 5.43 | 6.40 | 0.8379 | 1.06 | 13.76 | 991,630.20 | 10.84 | -- | 12.63 | -- | 93.32 | -- | 12.94 | -- | 5.20 | -- | 0.00 | -- | 1,612.94 | -- | 124.84 | -- | -- | -- |
| Leap Therapeutics Inc | 0.00 | -81.41m | 121.29m | 54.00 | -- | 1.35 | -- | -- | -5.11 | -5.11 | 0.00 | 2.35 | 0.00 | -- | -- | 0.00 | -113.72 | -80.06 | -136.52 | -95.03 | -- | -- | -- | -7,900.37 | -- | -- | 0.00 | -- | -- | -- | -49.12 | -- | -- | -- |
| Coya Therapeutics Inc | 6.00m | -7.99m | 123.10m | 8.00 | -- | 3.41 | -- | 20.51 | -0.8219 | -0.8219 | 0.5906 | 2.47 | 0.2417 | -- | -- | 750,276.30 | -32.17 | -- | -39.17 | -- | -- | -- | -133.08 | -- | -- | -- | 0.00 | -- | -- | -- | 34.77 | -- | -- | -- |
| Karyopharm Therapeutics Inc | 146.03m | -143.10m | 123.45m | 325.00 | -- | -- | -- | 0.8454 | -1.25 | -1.25 | 1.28 | -1.19 | 0.4879 | 1.36 | 3.94 | 449,332.30 | -47.81 | -53.02 | -61.78 | -65.85 | 96.62 | 97.18 | -97.99 | -125.15 | 3.32 | -10.06 | 1.81 | -- | -7.03 | 36.93 | 13.43 | -- | -- | -- |
| Sagimet Biosciences Inc | 2.00m | -27.88m | 125.11m | 10.00 | -- | 0.9856 | -- | 62.55 | -1.31 | -1.31 | 0.0937 | 3.98 | -- | -- | -- | 200,000.00 | -- | -- | -- | -- | -- | -- | -1,393.80 | -- | -- | -- | 0.00 | -- | -- | -- | 8.60 | -- | -- | -- |
| Vistagen Therapeutics Inc | 1.04m | -32.07m | 127.02m | 37.00 | -- | 1.03 | -- | 121.86 | -3.56 | -3.56 | 0.0775 | 4.56 | 0.013 | -- | -- | 31,584.85 | -39.89 | -77.80 | -42.10 | -85.00 | -- | -- | -3,076.62 | -8,640.25 | -- | -- | 0.00006 | -- | -120.50 | -- | -21.64 | -- | 165.73 | -- |
| FitLife Brands Inc | 52.70m | 5.30m | 128.75m | 37.00 | 25.90 | 4.76 | 23.89 | 2.44 | 1.08 | 1.08 | 10.74 | 5.88 | 1.30 | 3.44 | 38.31 | 1,424,297.00 | 13.07 | 26.40 | 15.94 | 33.92 | 40.67 | 42.09 | 10.05 | 17.65 | 0.5419 | 16.81 | 0.4253 | -- | 82.97 | 25.28 | 19.58 | 67.31 | -- | -- |
| Omega Therapeutics Inc | 3.10m | -97.43m | 129.61m | 93.00 | -- | 2.23 | -- | 41.88 | -1.81 | -1.81 | 0.0573 | 1.05 | 0.0177 | -- | 0.9172 | 33,279.57 | -55.62 | -- | -64.61 | -- | -- | -- | -3,147.92 | -- | -- | -- | 0.2456 | -- | 49.25 | -- | 5.13 | -- | -- | -- |
| Tevogen Bio Holdings Inc | 0.00 | -62.57m | 131.54m | -- | -- | -- | -- | -- | -0.4043 | -0.4043 | 0.00 | -0.5867 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -8.74 | 42.99 | -- | -- | -- | -41.32 | -- | -- | -- |
Data as of Apr 26 2024. Currency figures normalised to Karyopharm Therapeutics Inc's reporting currency: US Dollar USD
38.07%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2023 | 8.48m | 7.37% |
| Avidity Partners Management LPas of 31 Dec 2023 | 8.30m | 7.21% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 8.16m | 7.09% |
| Palo Alto Investors LPas of 31 Dec 2023 | 5.10m | 4.43% |
| Citadel Advisors LLCas of 31 Dec 2023 | 3.10m | 2.70% |
| Geode Capital Management LLCas of 31 Dec 2023 | 2.38m | 2.07% |
| GSA Capital Partners LLPas of 31 Dec 2023 | 2.34m | 2.03% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 2.05m | 1.79% |
| Renaissance Technologies LLCas of 31 Dec 2023 | 1.96m | 1.71% |
| Marshall Wace LLPas of 31 Dec 2023 | 1.93m | 1.67% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
